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Cardiovascular disease is a leading cause of death worldwide and is caused by the build up of
atherosclerotic plaques in the vasculature. It is now well established that the formation of these plaques
is closely related to levels of both high density lipoprotein (HDL) and low density lipoprotein (LDL)
cholesterol. Thus, the importance of the effective measurement of these is critical for the improved
diagnosis and management of atherosclerosis. This review discusses the emergence of methodologies
for the selective determination of both LDL and HDL cholesterol. It begins with an explanation of the
first methodologies based on ultracentrifugation and precipitation techniques, the development of
reference methods, through to the emergence of methodologies suitable for routine laboratory use,
followed by the development of professional use, point of care technologies. Finally, the current status
of selective tests for cholesterol based on biosensor methodologies is reviewed and the potential for
application in consumer diagnostics is discussed.Introduction
Coronary artery disease is the number one cause of death in all
developed countries.1 In the 1980s, public concern over the risks
of high blood cholesterol levels began to rise. Since then, several
studies have demonstrated the increased risk of cardiovascular
diseases including arteriosclerosis due to high cholesterolrs Termeh Ahmadraji is a
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3625levels. As a result, cholesterol has become one of the main
parameters which are measured in routine clinical laboratory
testing, accounting for an increase in demand for cholesterol
testing technology in the last few years.2–4 Atherosclerosis is a
condition in which arteries become blocked partly due to the
accumulation of cholesterol. When cholesterol deposits on the
walls of arteries, plaques form which may lead to blockages and
interruption of the circulation, causing angina and myocardial
infarction, with their associated morbidity and mortality. Some
plaques can burst which can lead to thromboembolism.5Prof. Tony Killard received his
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Fig. 1 Chemical structure of (a) cholesterol, and (b) cholesteryl ester.6
Critical Review Analytical MethodsCholesterol (including cholesteryl esters), phospholipids
(PLs), and triglycerides (TGs) are three major types of lipid
present in the plasma. Cholesterol [(3b)-cholest-5-en-3-ol] is by
far the most abundant member of a family of polycyclic
compounds known as sterols. Cholesterol in plasma lipoprotein
can be found in the free form, esteried to long-chain fatty acids
(cholesteryl esters), and in other covalent and non-covalent
linkages in animal tissues.7 The chemical structures of choles-
terol and cholesteryl ester are shown in Fig. 1.
Since lipids are not readily soluble in water, only small
amounts are present as unesteried cholesterol. To allow
adequate transport of cholesterol and other lipids, lipoproteins
form a coat around the lipids in order to suspend them in the
plasma. Lipoproteins are particles composed of lipid and protein
which are held together with noncovalent bonds. They consist of a
nonpolar lipid core of mainly cholesteryl ester and triacylglycerols
and an outer layer of phospholipids, unesteried cholesterol and
proteins (Fig. 2). The function of the lipoprotein particle is to
transport lipids such as cholesterol or triglycerides around the
body via the blood stream. Based on the relative densities of these
species, chylomicron (CM), very low-density lipoprotein (VLDL),
low-density lipoprotein (LDL) and high-density lipoprotein (HDL)
are the four major categories of lipoprotein.4
Lipoproteins have unique physical and chemical character-
istics, particularly with respect to their relative amount of lipids,
protein–lipid ratio and specic protein species present (Table
1). Since lipoproteins vary in size and density, centrifugation
techniques have been used to separate them and distinguish
them from each other. LDL and HDL are the two major lipo-
proteins found in humans, and are responsible for carryingFig. 2 General structure of lipoproteins. Adapted from Griffin (2009).10
This journal is ª The Royal Society of Chemistry 2013cholesterol in the blood. The lipid cores of HDL and LDL
contain cholesteryl esters (CEs) and TGs surrounded by PLs,
unesteried cholesterol and specialized proteins known as
apolipoproteins (Fig. 2). The CEs are enriched in linoleate,
reecting their biosynthetic origin. Apolipoproteins are
amphipathic in nature which can interact with lipid moieties of
lipoproteins and the aqueous environment and are specialized
to facilitate several biochemical steps associated with plasma
lipid metabolism.11–13 Plasma apolipoprotein can be classied
as the non-exchangeable apolipoproteins (e.g. apo B-100) and
the exchangeable apolipoproteins (e.g. apo A-I, apo A-II).12
LDL particles with a density range between 1.019 and 1.063 kg
L1 carry 60–70% of the total serum cholesterol. A single apoli-
poprotein, apo B-100 is the only protein component of LDL,
which is highly insoluble in aqueous solution and is the largest
monomeric protein known.12 Since apo B-100 is highly insoluble
in aqueous solution, it remains with the lipoprotein particle
throughout its metabolism.14 Fig. 3 is a schematic of the LDL
consensus model summarizing the proposed organization of
lipid: Hydrophobic core lipid including cholesterol ester and
TGs, hydrophilic shell of phospholipid and unesteried choles-
terol.12 LDL is the major atherogenic lipoprotein and has long
been identied by the National Cholesterol Education Program
(NCEP) as the primary target of cholesterol lowering therapy. The
importance of reducing the risk of coronary heart disease (CHD)
by lowering LDL-C has been shown by clinical trials.15,16
HDL is the smallest lipoprotein, which normally carries 20–
30% of the total serum cholesterol (HDL-C). Apo A-I and apo A-II
are the two major apolipoproteins of HDL. They are both clas-
sied as exchangeable amphipathic apolipoproteins and are
soluble in aqueous solutions. All the apolipoproteins, other
than apo B-100, have a helical structure with a hydrophobic
and a hydrophilic domain. The hydrophobic domain of theFig. 3 LDL consensus model.
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Table 1 Classification of lipoproteinsa
Classb Density (kg L1) Diameter (nm) Protein (%)
Free
cholesterol (%)
Cholesteryl
ester (%) Phospholipids (%) Triglycerides (%)
HDL 1.063–1.21 8–15 33 7 40 46 6
LDL 1.019–1.063 18–24 25 11 50 29 10
VLDL 0.95–1.006 30–52 10 7 18 20 55
CM <0.95 80–1200 <2 2 3 8 85
a Adapted from Garrett and Grisham (1995),8 Rifai et al. (2001)9 and Griffin (2009).10 b HDL: high density lipoprotein; LDL: low density lipoprotein;
VLDL: very low density lipoprotein; CM: chylomicron.
Table 2 ATP III Classification of total cholesterol, LDL Cholesterol and HDL
cholesterol. Reproduced from ATP III report (2001)3
Analyte Concentration (mg dL1) Classication
Total cholesterol <200 Desirable
200–29 Borderline high
$240 High
LDL cholesterol <100 Optimal
100–129 Near or above optimal
130–159 Borderline high
160–189 High
$190 Very high
HDL cholesterol <40 Low
$60 High
Analytical Methods Critical Reviewapolipoprotein interacts with the lipid, while the hydrophilic
domain orientates itself towards the aqueous phase.15 The main
protein component ofHDL is apoA-I, ofwhich70%is synthesized
within the liver and the rest in the intestine.7 Fig. 4 illustrates that
nascent HDL (HDL3) is secreted by the liver and intestines and is
transformed into mature HDL2 by the action of the lecithin-
cholesterol acyltransferase (LCAT). HDL3 is discoid in structure
and contains apo A-I, phospholipids and free cholesterol while
HDL2 is round, mature and contains esteried cholesterol.17
Although HDL-C levels are inversely correlated with the risk
of CHD,18 the value of treating low HDL-C is not as well estab-
lished as treating high LDL-C. Most treatment options for
lowering high LDL-C levels such as physical exercise, weight
loss and even some of the cholesterol lowering drugs, have also
demonstrated a benecial effect on HDL-C concentration.15,19Fig. 4 The metabolic origins of HDL. With permission from Rye and Barter (2012).17
3614 | Anal. Methods, 2013, 5, 3612–3625Importance of standardisation of
measurement for HDL-C and LDL-C
Since low HDL-C and high LDL-C levels are linked to increased
risk of heart attack,4,20 the importance of accurate measurement
of both HDL-C and LDL-C has been emphasized by the National
Cholesterol Education Program (NCEP).3,15,21–23 The NCEP is a
program managed by the US National Heart, Lung and Blood
Institute which established the laboratory standardisation
panel on blood cholesterol measurement in order to assess the
reliability of cholesterol measurement in clinical laboratories
and improve the precision and accuracy of cholesterol testing.9
The main reason for standardisation is to ensure the agreement
of reported results across measurement systems, laboratories
and over time.24
Table 2 shows the classication of serum total cholesterol
(TC), LDL and HDL as summarised in the third report of the
expert panel on detection, evaluation, and treatment of high
Blood Cholesterol in Adults (Adult Treatment Panel III, or ATP
III) presenting the NCEP's updated recommendations for
cholesterol testing and management.3 Based on the clinical
need to reliably categorise patients, the NCEP established
analytical performance goals for measurement of the total
cholesterol, HDL-C and LDL-C (Table 3).21,25The development of routine methods for the
measurement of HDL and LDL cholesterol
Given the fact that lipoproteins are dened by their density,
one of the rst separation methods used to differentiate
between HDL-C and LDL-C and other lipoproteins wasThis journal is ª The Royal Society of Chemistry 2013
Table 3 NCEP criteria for TC, HDL-C and LDL-C testing. Reproduced from ATP III
report (2001) (ref. 3)a
Analyte Inaccuracy Imprecision Total error
TC #3% RM CV # 3% #8.9%
HDL-C #5% RM SD # 1.7 AT (<42 mg dL1) #13%
CV # 4.0% at ($42 mg dL1)
LDL-C #4% RM CV # 4% #12%
a RM ¼ reference value assigned by CDC reference measurement
procedure, CV ¼ coefficient of variation, SD ¼ standard deviation.
Critical Review Analytical Methodsultracentrifugation. However, since ultracentrifugation
methods are tedious, time consuming and do not easily achieve
complete and reproducible recovery, this approach is not
considered practical for use in clinical laboratories.9,15,19,26
However, ultracentrifugation is still considered as the basis of
reference methods for measuring HDL and LDL choles-
terol.21,24,25,27 Since lipoproteins are a heterogeneous mixture of
lipids and proteins which are not strictly dened, a signicant
overlap can exist in the physical properties of the major lipo-
protein classes. Therefore, a primary referencemethod for HDL-
C and LDL-C measurement has not been developed.24 The most
common approach used to determine LDL-C in the clinical
laboratory is the Friedewald calculation.16,28 The principle of the
Friedewald calculation is as follows:
1. TC is distributed among the three major lipoprotein
classes (HDL, LDL and VLDL).
2. VLDL carries most of the circulating TGs and therefore
VLDL-cholesterol (VLDL-C) can be estimated reasonably well
from measured total TGs (TG/5 for mg dL1 or TG/2.2 for mM
units).
3. LDL-C is then calculated as:
LDL-C ¼ TCHDL-C TG
5

mg dL1

(1)
LDL-C ¼ TCHDL-C TG
2:22
ðmMÞ (2)
This method is the most commonly used method in the
clinical laboratory and in large scale studies. Although the
Friedewald method is widely used, the well-known limitation of
this method29–33 increases the interest in improving the accu-
racy of LDL-C estimated by this equation.34 The Centers for
Disease Control and Prevention (CDC) use a reference method
(RM) based on the Lipid Research Clinic's (LRC) beta-quanti-
cation procedure (BQ) for measuring LDL-cholesterol.9,35 In this
method an aliquot of plasma is ultracentrifuged at density
1.006 kg L1 for at least 18 h at 105 000g to accumulate the
VLDL as a oating layer. The amount of LDL-C is then calcu-
lated using eqn (3):9,16,26
LDL-C ¼ [d 1.006 kg L1 bottom fraction cholesterol
 HDL-C] (3)
Accuracy in the HDL-C measurement has also been impor-
tant for the calculation of LDL-C using the Friedewald formula.
As recommended by NCEP, the CDC method is the currentThis journal is ª The Royal Society of Chemistry 2013secondary reference method for HDL-Cmeasurement.21,24 There
are three key steps to this method:
1. Ultracentrifugation at a density of 1.006 kg L1 to isolate
HDL and LDL from other lipoproteins.
2. Selective precipitation of LDL with heparin/MnCl2.
3. Analysis of cholesterol in the HDL (supernatant) using the
Abell-Kendall assay.9
Since there are only a few laboratories capable of performing
the ultracentrifugation steps necessary in the CDCmethod, and
due to the high volume (greater than 5.0 mL) of sample
required, the Cholesterol Reference Method Laboratory
Network (CRMLN) also developed the Designated Comparison
Method (DCM) based on a modied dextran sulphate proce-
dure.36 This method uses 50 kDa dextran sulphate with MnCl2
for the precipitation of non-HDL, followed by measurement of
the cholesterol in the supernatant by the CDC reference
method. Other than reference methods based on ultracentri-
fugation, laboratory based tests using electrophoresis, chro-
matography and spectrophotometry have been developed.
Electrophoresis
Due to the differences in the size and charge of various lipo-
proteins, isolation can be also achieved using electrophoresis
techniques, with visualization achieved using lipophilic dyes.19
However, due to the fact that the lipophilic dyes are not specic
for a class of lipid such as cholesterol, TGs or PLs, these tech-
niques cannot be used for quantitative analysis, but can be used
for qualitative analysis of lipoproteins.9,37,38 Visual presentation
is a distinct advantage of the electrophoretic methods facili-
tating observation of atypical lipoproteins. For the routine
clinical laboratory, both ultracentrifugation and electrophoresis
have disadvantages especially when the workload is high.
In the last decade, there has been signicant progress in the
development of microsystems applied to separation techniques
such as capillary electrophoresis.39 Ruecha et al. (2011) have
proposed a method for rapid detection of cholesterol using
poly(dimethylsiloxane) microchip capillary electrophoresis
(PDMS MCE) based on the coupling of enzymatic assays and
electrochemical detection.40 Such techniques, could, in the
future, have the potential for selective determination of HDL-C
and LDL-C at the point of care.
Chromatography
A variety of HPLC methods have been used to separate lipo-
proteins such as HDL, LDL, VLDL and CM, but this has been
impeded by the poor stability of the columns used for separa-
tion.19,26 Even improved HPLC techniques which separate serum
lipoproteins based on their size using two connected columns
with subsequent determination of cholesterol concentration
using an online enzymatic reaction cannot be used in the
routine clinical laboratory.41–44
Recently Dong et al. (2011) have established a new method
for determination of HDL and LDL cholesterol using ultracen-
trifugation and HPLC.45,46 Ultracentrifugation is used to sepa-
rate HDL and LDL subfractions and Lipoprotein (a). Cholesterol
levels in the ultracentrifugal bottom fractions were analyzed byAnal. Methods, 2013, 5, 3612–3625 | 3615
Analytical Methods Critical ReviewHPLC.46While this method requires substantially less specimen
volume when compared to other separation methods, it still
requires the use of ultracentrifugation which is not applicable
to clinical measurement.Spectrophotometry
Due to its widespread adoption and simple methodology, many
spectrophotometric methods have been developed to measure
HDL-C and LDL-C. Initially, cholesterol was measured using
non-enzymatic spectrophotometry in the form of the Lie-
bermann–Burchard (L–B) and Killani–Zak assays.47 The L–B
reaction is performed in an acetic acid–sulphuric acid–acetic
anhydride medium based on the fact that cholesterol reacts
with various strong acids of the Bronsted and Lewis types to
yield coloured products. The Killani–Zak assay was based on
direct treatment of the serum with a reagent composed of ferric
chloride dissolved in a glacial acetic acid–sulphuric acid
mixture.48 However, poor specicity, instability of the colori-
metric reagent, and standardization difficulties were some of
the disadvantages of this method.49 The selectivity of spectro-
photometric methods was improved signicantly by using
enzymes such as cholesterol esterase (ChEs), cholesterol
oxidase (ChOx) and horseradish peroxidase (HRP) (Fig. 5).50
Where 4AAP is 4-aminoantipyrine and Trinder's dye is an
enhancer such as phenol. Measuring the amount of O2
consumed or the levels of H2O2 produced are the preferred
methods of quantifying cholesterol spectrophotometrically.
Due to the consumption of oxygen by other substances such as
ascorbic acid in clinical samples, any method measuring the
amount of oxygen consumed in Fig. 5 is not accurate.2 There-
fore, measuring the amount of H2O2 produced was found to be
a more accurate method of quantifying blood total choles-
terol.50,51 In this method, the H2O2 generated in the presence of
4AAP, phenol and HRP forms a quinoneimine dye, which can be
measured at 500 nm by spectrophotometry.
For the selective measurement of HDL-C or LDL-C, two
additional aspects of the assay need to be employed. Firstly, the
enzymes must gain effective access to the cholesterol associated
with the lipoprotein fraction. Secondly, the enzymes must also
only gain access to the cholesterol from the specic lipoprotein
fraction to be measured and be preventing from catalysing
cholesterol in other fractions. In the following sections, some of
the approaches that have been used for measuring HDL-C and
LDL-C will be reviewed.Selective methods of HDL and LDL
cholesterol measurement
Chemical precipitation methods
In chemical precipitation methods, lipoproteins other than the
target, e.g., HDL-C are aggregated and rendered insoluble using
polyanions in combination with divalent cations which can
then be sedimented by low-speed centrifugation, while HDL
remains soluble.9 The supernatant containing HDL-C can then
be recovered for cholesterol analysis. The specicmechanism of
lipoprotein precipitation by polyanions and divalent cations has3616 | Anal. Methods, 2013, 5, 3612–3625not yet been fully elucidated.52 However, it is important to
consider the interaction between negatively charged groups on
the polyanions and positively charged groups on the protein
moieties of the lipoproteins.53 Divalent metal ions interact with
negatively charged groups (such as phospholipids) on the
lipoproteins to facilitate formation of insoluble complexes.52,53
The larger, more lipid-rich lipoproteins such as VLDL and LDL,
form insoluble complexes more readily than the smaller,
protein-rich HDL. The insoluble complexes may either remain
suspended in the solution or oat to the surface in the presence
of high concentrations of TG-rich lipoproteins. Heparin–Mn2+
has been a popular polyanion/divalent ion combination which
has been used to assign target values to reference materials.54
Since commercial heparin showed some inconsistency in its
properties for routine use, dextran sulphate–Mg2+ (50 kDa),52
phosphotungstic acid–Mg2+ (ref. 55) and polyethylene glycol
(PEG)56 have been used as alternatives.
LDL particles can also be precipitated using certain reagents.
The amount of LDL-C is determined by subtracting the choles-
terol measured in the supernatant from the total cholesterol.
Alternatively, the precipitate could be dissolved to measure the
level of LDL-C directly.26 A number of reagent formulations have
been used for the selective precipitation of LDL-C including:
heparin at pH 5.12 in sodium citrate buffer; polyvinyl sulphate
(PVS) in EDTA; PEG methyl ether; unspecied amphipathic
polymers in imidazole buffer, at pH 6.10.57 These precipitation
methods did not show noticeable advantages in precision and
accuracy compared to the Friedewald calculation.Homogeneous methods
Homogeneous assays were a major step forward in improving
the precision of earlier precipitation methods. Full automation
eliminated manual pipetting, off-line pre-treatment, centrifu-
gation and separation steps and improved assay precision, in
line with recommended NCEP criteria. The development of such
assays has been an area of intense commercial research and
development dominated by several Japanese companies
including Kyowa Medex, Seikisui Medical (formerly Daiichi Pure
Chemicals Company), Deneka Seiken Co., Kokusai or Sysmex
International Reagents (formerly International Reagents
Corporation, IRC), Wako Chemicals, UMA and Serotec.58 The
precise mechanisms involved in the interaction between the
lipoproteins and the assay reagents used in these assays remain
unclear.59 Fig. 6 illustrates a generalised approach to the selec-
tive detection of HDL-C in the presence of other lipoproteins
using the homogeneous principle. A brief description of the
principles of each of the homogeneous HDL-C assay methodol-
ogies is given in the following section and their reaction mech-
anisms and performance characteristics summarised in Table 4.
In their review, Warnick et al. (2001) described the methods
of Kyowa Medex, Daiichi, Deneka, International Reagents
Corporation (IRC) and Wako for HDL-C in detail and compared
them with conventional assay methods.19 The authors reported
that all ve methods demonstrated acceptable accuracy, preci-
sion and total error by meeting the NCEP criteria, making them
suitable for clinical application.This journal is ª The Royal Society of Chemistry 2013
Fig. 5 Spectrophotometric measurement of cholesteryl ester and cholesterol using cholesterol esterase (ChEs) and cholesterol oxidase (ChOx). The generation of H2O2
is detected using horseradish peroxidase (HRP) in the presence of 4-aminoantipyrine (4-APP) and phenol, generating a quinoneimine dye which is measured at 500 nm.
Critical Review Analytical MethodsIRC was the rst to publish a report of a HDL-C fully auto-
matable homogeneous assay based on an immunological
separation method in 1994. Based on this method, CM, VLDL
and LDL were rst aggregated using a reagent containing PEG
and then protected with antibodies to apo B and apo C. In the
next step, unprotected HDL-C underwent enzymatic reaction as
described in Fig. 5.19 In the nal step, guanidine salts were used
to stop the enzymatic reaction and clear the reaction mixture.
The nal absorbance was measured at 600 and 700 nm.9,19 In
spite of the fact that this assay showed reasonable precision,
accuracy and specicity, the addition of four different reagents
limited its application to a small number of automated
analyzers.60 Later on Kokusai (formerly IRC) developed a new
reagent containing calixarene to produce a soluble complex of
non-HDL–calixarene.61
In 1995, Kyowa Medex reported a homogeneous assay for
HDL-C. Based on this method, the combination of PEG-modi-
ed enzymes with a-cyclodextrin sulphate provided selectivity
for the determination of HDL C in serum in the presence of a
small amount of dextran sulphate with no need for precipita-
tion of lipoprotein aggregates. PEG-modied ChEs and ChOx
showed selective catalytic activity toward lipoprotein fractions.
The reactivity increased in the order LDL < VLDL z CM <
HDL.62 Although the mechanism for the selectivity of the
modied enzymes towards the lipoprotein fractions is not clear,
it is suggested that the modied enzymes may be able to
recognize differences in hydrated density, net charge, or size of
the various lipoprotein fractions. Size-exclusion chromatog-
raphy revealed that PEG-modied ChEs breaks up the lipopro-
tein particles more effectively than the native enzyme, probablyThis journal is ª The Royal Society of Chemistry 2013because of the amphiphilic properties of the attached PEG
molecules.62 Therefore, HDL should be more susceptible to the
modied enzyme than LDL, explaining the observed differences
in reactivities of cholesterol moieties of the lipoprotein frac-
tions. H2O2 generated from the enzymatic reaction is measured
spectrophotometrically.19,62,63 This method was evaluated in
several studies including comparison with RM and DCM
methods, which showed correlations of 0.993 and 0.996,
respectively.15
Daiichi developed a homogeneous assay for HDL-C which
employed a synthetic polymer together with a polyanion to
block the non-HDL lipoproteins.19 Cholesterol in HDL was then
exposed to the enzymes in the presence of a selective detergent
which gives specicity for HDL-C.64,65 Kondo et al. (1999) visu-
alized the formation of HDL–polymer complexes aer the
addition of polymer and polyanion (the rst reaction) using
electron microscopy. This showed that this complex breaks
down in the presence of a detergent in the second reaction. It
also showed that the polyanion in reagent 1 (phosphotungstate)
caused the aggregation of almost all lipoprotein. However, the
exact roles of the polyanion and synthetic polymer remain
unknown.59 Commercial reagent sets included two reagent
additions; the rst with the polyanion and polymer blocking
agents and the second with detergent, enzymes, and substrates.
The specicity and analytical performance of this method was
investigated and published in several studies.59,66–68
Kurosaki et al. (2009) have reported that with the Daiichi
method, free cholesterol in serum was eliminated in the rst
reaction, and free cholesterol in HDL was not measured.69 Later
on in 2009, Daiichi published a patent regarding its modiedAnal. Methods, 2013, 5, 3612–3625 | 3617
Fig. 6 Generalised homogeneous assay methodology for the selective determination of HDL-C. A blocking reagent selectively prevents access of a specific surfactant
to the non-HDL lipoproteins. Addition of the surfactant selectively solubilises the HDL, allowing access to cholesterol esterase (ChEs) and cholesterol oxidase (ChOx). The
generated H2O2 can then be measured in the conventional manner.
Analytical Methods Critical Reviewmethod.70 In a rst reaction, free cholesterol on the surface of
only LDL and VLDL reacts with ChEs and ChOx. The H2O2
produced in the reaction is eliminated by peroxidase; thus no
colour formation occurs in response to free cholesterol. In the
second step, a special detergent causes only HDL to be dissolved
to allow the reaction between HDL-C and the enzyme. As a
detergent, a polyoxyethylene derivative such as Emulgen B-66 or
Emulgen-90 (Kao Corporation, Japan), which directly hydrolyzes
the HDL particles can be used.70–72 Using this methodology,
HDL-C could be conveniently quantied without resort to the
use of polyanions as in their original method.
Wako Chemicals introduced a more convenient immu-
noinhibition homogeneous assay using anti human-b-lipopro-
teins to produce soluble complexes of CM, VLDL and LDL with
no reaction with enzymes involved in subsequent enzymatic
cholesterol reaction. Only the cholesterol content of HDL is
measured in the presence of enzymes in the second reagent.66,73
The HDL-C method developed by Deneka Seiken Co. was
based on the fact that non-HDL-C selectively reacts with the
ChEs and ChOx in the rst step without producing any colour.
H2O2 produced in this step is scavenged by the enzyme catalase.
In the next step, in the presence of a reagent containing a3618 | Anal. Methods, 2013, 5, 3612–3625surfactant to solubilise HDL-C, an inhibitor of catalase, 4-AAP
and N-(2 hydroxy-3sulfopropyl)-3,5-dimethoxyaniline (HDAOS),
colour is developed.19,74
Finally according to the phosphate complex inhibition
method introduced by Serotec and UMA, HDL-C in the presence
of a detergent and phosphate compound undergoes an enzy-
matic reaction.61
According to the homogeneous method for LDL-C, lipopro-
teins other than LDL such as VLDL, HDL and CM are removed in
the rst step using the rst reagent described by eachmethod. In
the second stage, LDL-cholesterol undergoes an enzymatic reac-
tion to produce hydrogen peroxide which is measured colori-
metrically.26,33 Various physicochemical combinations of
surfactants, polymeric complexes and specic binding molecules
were also used in establishing homogeneous assays to selectively
measure LDL-C.75 Although the mechanism that confers selec-
tivity to LDL-C from a specic surfactant is also not well under-
stood, the same general mechanism is thought to apply as for
HDL-C in that the surfactant may be able to distinguish differ-
ences in hydrated density, net charge, or size of the various
lipoprotein fractions.76,77 A brief description of the principles of
each of the homogeneous LDL-C assay methodologies is given inThis journal is ª The Royal Society of Chemistry 2013
Table 4 Schematic reaction mechanism for HDL-C Assay kits and their performance. Adapted from Nakamura et al. (2006) (ref. 61)a
Assay kits Performance and others
Daiichi (accelerator selective detergent method)
First step: Dynamic range: 1.5–150 mg dL1
1. Non-HDLs + synthetic polymers + polyanions/ soluble
complexes of non-HDL
Not measurable in presence of abnormal lipoprotein caused by sever
liver dysfunction.
Second step: No interference by TG value at up to 1500 mg dL1
2. HDL-C + selective detergent + ChEs + ChOx/ cholestenone + fatty
acid + H2O2
No interference by hemoglobin at up to 500 mg dL1
3. H2O2 + 4AAP/peroxidase + DSBmT/ color development No interference by bilirubin at up to 50 mg dL
1
Recommended sample storage: one-week under refrigeration,
sample can be frozen-thawed only once.
Kyowa Medex (modied enzymatic method)
First step: Dynamic range: 0–120 mg dL1
1. Non-HDLs + a-cyclodextrin + MgCl/ soluble complexes of non-
HDL
No interference by TG value at up to 1200 mg dL1
Second step: No interference by hemoglobin at up to 1200 mg dL1
2. HDL-C + PEG modied ChEs and ChOx/ cholestenone + fatty
acid + H2O2
No interference by bilirubin at up to 30 mg dL1 (conjugated form)
and 70 mg dL1 free form
3. H2O2 + 4AAP/peroxidase + HDAOS/ color development Recommended sample storage: one-week under refrigeration,
sample can be frozen-thawed only once.
Kokusai or Sysmex (calixarene complex method)
First step: Dynamic range: 1.5–100 mg dL1
1. Non-HDLs + calixarene/ non-HDL–calixarene soluble complex Negative predictive value or the samples of liver dysfunction and
positive value in presence of LDL fractions and apo E-rich serum
Second step: No interference by TG value at up to 1500 mg dL1
2. HDL-C + ChEs + ChOx + hydrazine + b-NAD/ cholestenone
hydrazone + b-NADH
No interference by hemoglobin at up to 500 mg dL1
+ ChEs from Chromobacterium viscosum cannot react to the non-
HDL–calixarene soluble complex.
No interference by bilirubin at up to 20 mg dL1
Recommended sample storage: three days under refrigeration,
sample can be frozen only once at 80 C.
Wako (immunoinhibition method)
First step: Dynamic range: 1–180 mg dL1
1. Non-HDLs + anti human-b-lipoprotein/ soluble complexes of
non-HDL
Positive value in presence of LDL, VLDL and apo E-rich HDL
Second step: No interference by TG value at up to 1200 mg dL1
2. HDL-C + ChEs + ChOx/ cholestenone + fatty acid + H2O2 No interference by hemoglobin at up to 500 mg dL
1
3. H2O2 + 4AAP/peroxidase + F-DAOS/ color development No interference by bilirubin at up to 50 mg dL
1
Recommended sample storage: four days under refrigeration,
sample can be frozen-thawed only once.
Serotec and UMA (phosphate complex inhibition method)
First step: Dynamic range: Up to 200 mg dL1
1. HDL-C + detergent and IP compound (inorganic/organic) + ChEs
/ free cholesterol + fatty acid
Positive value in presence of VLDL fractions
Second step: No interference by TG value at up to 1100 mg dL1
2. Free cholesterol + ChOx/ cholestenone + fatty acid + H2O2 No interference by hemoglobin at up to 500 mg dL
1
3. H2O2 + 4AAP/peroxidase + HDAOS/ color development No interference by free bilirubin at up to 40 mg dL
1 and6% in the
presence of 40 mg dL1 conjugated form
Recommended sample storage: one-week under refrigeration,
sample can be frozen-thawed only once at 20 C or lower.
Deneka Seiken (elimination method)
First step: Dynamic range: 1–150 mg dL1
1. Non-HDL-C + ChEs + ChOx/ cholestenone + fatty acid + H2O2 No interference by TG value at up to 1500 mg dL
1
2. H2O2 + catalase/ 2H2O + O2 No interference by hemoglobin at up to 500 mg dL
1
Second step: No interference by bilirubin at up to 30 mg dL1
3. HDL-C + detergent + ChEs + ChOx/ cholestenone + fatty acid +
H2O2
Recommended sample storage: one-week under refrigeration,
sample can be frozen-thawed only once.
4. H2O2 + 4AAP/peroxidase + HDAOS/ color development
a 4AAP: 4-aminoantipyrine, DSBmT: N,N-bis-(4-sulphobutyl)-m-toluidine, HDAOS: N-(2-hydroxy-3-sulphopropyl)-3,5-dimethoxyaniline, F-DAOS: N-
Ethyl-N-(2-hydroxy-3-sulphopropyl)-3,5-dimethoxy-4-uoroaniline.
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Analytical Methods Critical Reviewthe following section and their reaction mechanisms and
performance characteristics summarised in Table 5.
Nauck et al. (2002) have reviewed homogeneous methods for
LDL-C and compared them with conventional assay
methods.19,26 The rst LDL-C homogeneous assay was offered by
Kyowa Medex in 1998 and distributed by Roche Diagnostics.76
To provide the required selectivity, the combination of poly-
oxyethylene–polyoxypropylene (POE–POP) block co-polymer
with a-cyclodextrin sulfate was employed for the determination
of LDL-C, followed by reaction with ChEs and ChOx. MgCl2 and
a-cyclodextrin sulphate are rst used as a quencher for CMs and
VLDL-C and the POE–POP acts as a quencher for HDL-C.62,76
Due to the limited specicity of POE–POP toward LDL-C, the
LDL-C is selectively solubilised into mixed micelles and enzy-
matic reaction occurs. The level of selectivity toward LDL-C is
directly dependent on the molecular mass and hydrophobicity
of the POP blocks.62,76 This method was not found to be suffi-
ciently specic for LDL-C, since LDL is only partially recovered
and apo E-rich HDL and VLDL are not completely excluded.16,26
Daiichi reported a method employing non-ionic surfactant
to solubilise all non-LDL lipoproteins.26 Hydrogen peroxide
enzymatically generated in this step is then catalysed by a HRP
in the presence of 4-aminoantipyrene. No colour is produced in
this step. A second specic detergent is used to solubilise LDL-C
and generate hydrogen peroxide. The hydrogen peroxide in
presence of N,N0-bis-(4-sulphobutyl)-m-toluidine disodium salt,
HRP and 4-aminoantipyrene then generates colour which is
proportional to the level of LDL-C. The method is linear up to
1000 mg dL1, with the detection limit of 0.4 mg dL1 and
seems to be affected by increased TGs and is not completely
specic for LDL-C.16,26
The homogeneous LDL-C assay from Wako is based on rst
protecting LDL-C selectively from enzymatic reaction in the
presence of polyanions and amphoteric surfactants. As a result,
lipoprotein cholesterols other than LDL-C undergo enzymatic
catalysis and generate hydrogen peroxide which is consumed by
catalase. In the second step, a non-ionic surfactant as a de-
protection agent then enables the LDL-C to react with ChEs and
ChOx to produce hydrogen peroxide. The colour yield from the
reaction of hydrogen peroxide and Trinder's reagent and
4-aminoantipyrene is again measured spectrophotometrically.26
Total CVs at LDL-C concentrations between 103.4 and 219.6 mg
dL1 were 1.2% and total error ranged from 2.6% to 5.6%.78 The
method was found linear up to 300 mg dL1 with the detection
limit of 1.0 mg dL1.26 In spite of linearity issues and TG inter-
ference, the assay seems to be relatively specic for LDL-C.75,78
Deneka Seiken reported a homogeneous LDL-C assay using a
combination of two non-ionic surfactants (Emulgen B-66 and
Emulgen A-90) with a hydrophile–lipophile balance (HLB) of
13.5 which can selectively remove non-LDL-C in the presence of
MgCl2. Based on this method, the reactivity of cholesterol in
each lipoprotein depends on the HLB of the detergents.26,79 The
evaluation of this assay has been very limited. However, avail-
able data suggests that it has high specicity for LDL-C.
The method developed by IRC for LDL-C uses a calixarene as
a detergent which converts LDL to an LDL-calixarene soluble
complex. In the presence of ChEs (from Chromobacterium3620 | Anal. Methods, 2013, 5, 3612–3625viscosum), ChOx and hydrazine, cholesterol in the lipoproteins
other than LDL converts to cholestenone hydrazone. Finally the
LDL-calixarene complex is broken down aer the addition
deoxycholate, ChEs, ChOx and NAD, yielding cholestenone and
NADH. NADH is then measured spectrophotometrically.26,80,81
Finally according to the Serotec and UMA methodology, LDL-C
in presence of a selective detergent, phosphate compound and
cholesterol esterase produce free cholesterol. The free choles-
terol is determined according to Fig. 5.61
A multicentre evaluation of ve direct assays of LDL-C
(Daiichi, Denka Seiken, Kyowa and Wako) was performed using
45 serum samples (TG below 3.1 mmol L1) in eight laboratories
using different analysers.82 Inter-laboratory reproducibility was
improved markedly compared to the Friedewald calculation for
Daiichi, Kyowa and Wako. All the above mentioned methods
showed strong correlation in comparison with the BQ assay.
Miller et al. (2010) have compared some of the commercially
available homogeneous methods for measurement of HDL-C
and LDL-C with the RM for accuracy and total error. Specicity
and imprecision were also estimated. Table 6 shows that 5 of 7
HDL-C homogeneous methods reached the 95% acceptance
criteria for non-diseased individuals but deteriorated consid-
erably for the samples from the diseased group.
Only the Kyowa and Seikisui methods met total error goals
for measuring HDL-C in diseased individuals.58 None of the
LDL-C homogeneous methods met the criteria for the diseased
individuals and only four of them met the criteria for non-
diseased individuals.58
Iizuka et al. (2012) also compared homogeneous assay kits
for HDL and LDL cholesterol.83 The aim was to clarify the
commutability of currently used homogeneous assays to
measure HDL-C and LDL-C. It was shown that all of the above
mentioned HDL-C assay kits are commutable. Wako was the
only assay kit which showed discrepancy in the high bilirubin
samples. All the LDL-C assay kit results were affected by the
lipoprotein in the patient samples.83 Accuracy and precision
issues for the measurement of LDL-C have been reviewed in
several papers and the necessity of improving the accuracy of
LDL-C measurement has been emphasised.81,84–89Point of care testing (POCT) for HDL-C and LDL-C
In order to remove sample transport requirements, reduce
processing and assay times and facilitate near patient testing,
point of care devices that measure HDL-C and LDL-C directly
are very attractive in biomedical diagnostics. In general, point of
care testing needs relatively small volumes of whole blood
directly from a ngerstick and test results are available soon
aer sampling, which is highly advantageous in self-manage-
ment of hypercholesterolemia. There is no requirement for
transportation of samples to a central laboratory which helps to
reduce result turnaround time and transport costs. Earlier
diagnosis and disease management as well as potential for
improving patient satisfaction and cost-effectiveness are some
other advantages offered by POCT.90–92
A number of both professional use and consumer point of
care devices for measurement of cholesterol are commerciallyThis journal is ª The Royal Society of Chemistry 2013
Table 5 Schematic reaction mechanism for LDL-C Assay kits and their performance. Adapted from Nakamura et al. (2006) (ref. 61)a
Assay kits Performance and others
Daiichi (liquid selective detergent method)
First step: Dynamic range: 1–450 mg dL1
1. Surfactant 1 + ChEs/ChOx + CM, VLDL and HDL-C/
cholestenone + fatty acid + H2O2
No interference by TG value at up to 1500 mg dL1
2. 2H2O2 + catalase/ 2H2O + O2 No interference by hemoglobin at up to 500 mg dL
1
Second step: No interference by bilirubin at up to 20 mg dL1
3. LDL-C + surfactant 2 + ChEs/ChOx/peroxidase + DSBmT/ color
development
Recommended sample storage: one-week at 4 C, sample can be
frozen-thawed only once.
Kyowa Medex (selective solubilization method)
First step: Dynamic range: 0–550 mg dL1
1. Non-LDLs are blocked by surfactant and sugar compounds No interference by TG value at up to 1200 mg dL1
Second step: No interference by hemoglobin at up to 1500 mg dL1
2. LDL-C + surfactant + ChEs/ChOx/ cholestenone + fatty acid +
H2O2
No interference by bilirubin at up to 39 mg dL1 (conjugated form)
and 70 mg dL1 free form
3. H2O2 + 4AAP/peroxidase + HDAOS/ color development Recommended sample storage: one-week under refrigeration,
sample can be frozen-thawed only once.
Kokusai or Sysmex (calixarene complex method)
First step: Dynamic range: 1–350 mg dL1
1. LDL + calixarene/ LDL-calixarene soluble complex Positive predictive value in the presence of LDL fractions, apo E-rich
HDL and samples of liver dysfunction
Second step: No interference by TG value at up to 1500 mg dL1
2. CM, VLDL and HDL-C + ChEs(1)/ChOx + Hydrazine/
cholestenone hydrazone
No interference by hemoglobin at up to 500 mg dL1
+ ChEs (1) (from Chromobacterium), can not react with LDL-
calixarene soluble complex
No interference by bilirubin at up to 20 mg dL1
3. LDL-calixarene soluble complex + ChEs(2)/ChOx + hydrazine +
b-NAD + deoxycholate/ cholestenone hydrazone + b-NADH
Recommended sample storage: three days under refrigeration,
sample can be frozen only once at 80 C.
+ ChEs (2) (from Pseudomonas species)
Wako (enzyme selective protecting method)
First step: (elimination of non-LDL cholesterol) Dynamic range: 1.0–400 mg dL1
1. LDL + protecting reagent/ LDL-protecting reagent Positive predictive value in presence of VLDL fractions
2. CM, VLDL and HDL-C + ChEs/ChOx/ H2O2 + Catalase/ H2O No interference by TG value at up to 1000 mg dL
1
Second step: No interference by hemoglobin at up to 500 mg dL1
3. LDL-protecting reagent/ deprotecting reagent/ LDL No interference by bilirubin at up to 50 mg dL1
4. LDL-C + ChEs/ChOx/ cholestenone + H2O2 Recommended sample storage: one-week refrigeration, sample can
be frozen-thawed only once.
5. H2O2 + 4AAP/peroxidase + HDAOS/ color development
Serotec and UMA (phosphate complex inhibition method)
First step: Dynamic range: Up to 500 mg dL1
1. LDL-C + detergent and IP compound (inorganic/organic) + ChEs
/ free cholesterol + fatty acid
Positive value in presence of VLDL and LDL fractions
Second step: No interference by TG value at up to 1100 mg dL1
2. Free cholesterol + ChOx/ cholestenone + fatty acid + H2O2 No interference by hemoglobin at up to 500 mg dL
1
3. H2O2 + 4AAP/peroxidase + HDAOS/ Color development No interference by bilirubin at up to 40 mg dL
1
Recommended sample storage: one-week under refrigeration,
sample can be frozen-thawed only once at 20 C or lower.
Deneka Seiken (elimination method)
First step: Dynamic range: 1–800 mg dL1
1. Non-LDL-C + surfactant combination 1 + ChEs/ChOx/
cholestenone + fatty acid + H2O2
No interference by TG value at up to 1000 mg dL1
2. 2H2O2 + catalase/ 2H2O + O2 No interference by hemoglobin at up to 500 mg dL
1
Second step: No interference by bilirubin at up to 30 mg dL1
3. LDL-C + surfactant combination 2 + ChEs/ChOx/ cholestenone +
fatty acid + H2O2
Recommended sample storage: one-week under refrigeration,
sample can be frozen-thawed only once at 80 C.
4. H2O2 + 4AAP/peroxidase + HDAOS/ color development
a 4AAP: 4-aminoantipyrine, DSBmT: N,N-bis-(4-sulphobutyl)-m-toluidine, HDAOS: N-(2-hydroxy-3-sulphopropyl)-3,5-dimethoxyaniline, F-DAOS: N-
Ethyl-N-(2-hydroxy-3-sulphopropyl)-3,5-dimethoxy-4-uoroaniline.
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Table 6 Percentage total error results of a single measurement based on the
first result (no replication) for five homogeneous HDL-C and LDL-C assay
methods58
Method
% HDL-C
results
non-diseased
% HDL-C
results
diseased
% LDL-C
results
non-diseased
% LDL-C
results
diseased
Seikisui 100 96.4 100 91.1
Kyowa Medex 97.3 95.6 94.6 85.9
Deneka 100 92.7 89.2 85.2
Wako 100 74.5 97.3 87.4
Sysmex 100 89.8 86.5 71.9
UMA 91.9 83.9 97.3 75.6
Serotec 94.6 86.9 97.3 53.3
Fig. 7 (a) The Cholestech LDX point-of-care cholesterol analyser. (b) The
Cholestech LDX assay cartridge.
Analytical Methods Critical Reviewavailable. The Cardiocheck PA and Cholestech LDX are two
systems that support the UK NHS health check vascular risk
assessment.93 Cardiocheck PA is based on a spectrophotometric
method and the measurement of the light reected off a
disposable test strip that has changed colour aer applying
blood sample. The analyzer converts this reading into an HDL
result and displays it.94,95 The Cholestech LDX system combines
the enzymatic methodology and solid-phase technology to
measure the quantity of TC, HDL-C, TGs, glucose, and others in
the blood (capillary or venous), serum or plasma. The sample is
applied to a Cholestech LDX cassette (Fig. 7). The cassette is
then placed into the Cholestech LDX analyzer that can measure
the resultant colour by reectance photometry.96 The LDX uses
the Friedewald equation to calculate LDL-C while the
Cardiocheck PA measures LDL-C directly. A comparison
between Cholestech LDX POC and hospital reference laboratory
validates the use of the Cholestech LDX analyser for point of
care lipid measurements in clinical practice under well-trained
operators.97 A comparison between the performances of these
two point-of-care analyzers and clinical diagnostic laboratory
methods for the measurement of TC, HDL-C and LDL-C has
been reported.94,98 Both devices meet NCEP guidelines for all
analytes at two clinical cut-off points. Both of them were found
to have acceptable performance, which offers healthcare
professionals a rapid POC method for the measurement of
cholesterol in specic lipoproteins. Moreover, determination of
the accuracy and precision of TC, TG and HDL cholesterol
measures by a nurse on capillary blood using the Cardiocheck
system suggested that this approach was appropriate for pre-
dicting CHD risk and provided reliable fractionated lipid
information which was consistent with traditional clinical
chemistry platforms.99 The evolution of point of care tests from
professional use instruments towards low cost, consumer
diagnostics has been exemplied by the development of glucose
biosensors. The progression from optical to electrochemical
measurement methods is a natural evolution for many diag-
nostic devices as they progress from laboratory tests typically
based on spectrophotometry, to electrochemical devices which
allow lower cost instrumentation and system simplication.72,73
Cholesterol testing is also going through this evolution. Several
devices are available which can measure free cholesterol using
disposable electrochemical test strips. As with glucose,3622 | Anal. Methods, 2013, 5, 3612–3625cholesterol lends itself effectively to electrochemical measure-
ment as many of the transduction principles employed are
transferrable, such as the use of electron transfer mediators or
hydrogen peroxide to measure the oxidation of cholesterol.100–106
However, despite the growing importance of the selective
determination of LDL-C and HDL-C for monitoring and
managing hypercholesterolaemia, coupled with the suitability
of electrochemical assay methodologies to translate well to
cholesterol testing, there are still relatively few examples of
electrochemical biosensors capable of the selective determina-
tion of LDL-C and HDL-C.
Several sensor techniques such as quartz crystal microbal-
ance (QCM), surface plasmon resonance (SPR), cyclic voltam-
metry (CV) and electrochemical impedance spectroscopy (EIS)
have been employed to measure LDL quantitatively or qualita-
tively.107 Piezoelectric devices have been extensively investigated
as the basis for sensing due to their small size, small sample
requirements and high sensitivity.108 A piezoelectric LDL
biosensor was developed which was based on capturing and
detecting apo B-100 using interactions between its lysine rich
residues and immobilised components of the extracellular
matrix such as collagens and proteoglycans.107,109,110 However,
this was used to explore potential interactions between LDL and
the vasculature, rather than to quantify LDL-C levels In addi-
tion, although QCM biosensors have been found to be very
useful as laboratory-based investigative tools, their cost hasThis journal is ª The Royal Society of Chemistry 2013
Critical Review Analytical Methodsprohibited them from becoming the basis of consumer diag-
nostic devices.
Yan et al. (2008) reported a label-free electrochemical
immunosensor for LDL with a detection limit of 0.34 pgmL1.111
The electrode was fabricated using an antibody to apo B-100
adsorbed onto silver chloride–polyaniline (PANI) core–shell
nanocomposites (AgCl–PANI) at gold nanoparticle-modied
glassy carbon electrodes.111 The specic antibody–antigen reac-
tion facilitated the binding of a single apo-B-100 present in each
LDL to the electrode surface. The biosensor showed a highly
sensitive response to LDL with a detection limit of 0.34 pg mL1.
Due to the major focus in cholesterol testing on decreasing
LDL-C levels, there has only been a single report for the
amperometric determination of HDL-C.112 A peroxidase-entrap-
ped and ferrocene-embedded carbon paste electrode was used to
detect H2O2 at levels as low as 10 nM. The electrode was capable
of measuring HDL-C in a very small volume (1–2 mL) using PEG-
modied ChEs and ChEs in a manner analogous to the Kyowa
Medex assay. The PEG-modied enzymes exhibited a selective
activity toward HDL-C in the presence of dextran sulphate and
MgCl2 to generate H2O2. A comparison with the data obtained by
the equivalent spectrophotometric method as well as a conven-
tional precipitation method showed good correlation.Conclusion
The importance of the selective determination of both LDL-C
and HDL-C in determining atherogenic risk as well as moni-
toring the effectiveness of treatment for hypercholesterolemia is
now well-established. The implementation of effective testing
and monitoring regimes has been hampered by the availability
of suitable methods for their measurement. However, complex
methods based on precipitation and centrifugation have been
extensively replaced with simple homogeneous methods that
can be performed without the requirement for costly equipment
and skilled personnel. A number of point of care instruments
are also available for point of care testing of cholesterol levels.
However, while there are a number of consumer-based devices
for measuring free cholesterol, there are only a few examples of
sensor-based devices for performing selective measurements of
HDL-C and LDL-C, and none are available commercially. Given
the effective development of homogeneous methodologies
based on spectrophotometric measurement, it seems inevitable
that such methodologies will soon migrate onto electro-
chemical biosensor platforms suitable for consumer use. This
will, no doubt, improve the diagnosis and management of
hypercholesterolemia in a manner analogous to that achieved
for the management of diabetes with glucose test strips.Acknowledgements
The authors would like to acknowledge the nancial assistance
of EU, FP7/2007–2013, under Grant number 257372.Notes and references
1 M. Heron, Natl. Vital. Stat. Rep., 2012, 60, 1–95.This journal is ª The Royal Society of Chemistry 20132 M. D. Marazuela, B. Cuesta, M. C. Moreno-Bondi and
A. Quejido, Biosens. Bioelectron., 1997, 12, 233–240.
3 ATP III, Adult treatment panel III, JAMA, J. Am. Med. Assoc.,
2001, 285, 2486–2497.
4 Y. Zhang, J. Tuomilehto, P. Jousilahti, Y. Wang,
R. Antikainen and G. Hu, Stroke, 2012, 43, 1768–1774.
5 M. K. Campbell and S. O. Farrell, Biochemistry, Thomson
Brooks, Cole, Pacic Grove, CA, 2006.
6 M. Poirot, S. Silvente-Poirot and R. R. Weichselbaum, Curr.
Opin. Pharmacol., 2012, 12, 683–689.
7 W. W. Christie, Plasma lipoproteins: composition, structure
and biochemistry, AOCS lipid library, Dundee, Scotland,
2012.
8 R. H. Garrett and C. M. Grisham, Biochemistry, Saunders
College, Orlando, FL, 1995.
9 N. Rifai, R. Warnick and M. H. Dominiczak, Handbook of
Lipoprotein Testing, AACC Press, Washington, 2001.
10 B. A. Griffin, Surgery, 2009, 27, 1–7.
11 J. P. Segrest, M. K. Jones, H. D. Loof, C. G. Brouillette and
G. M. Anantharamaiah, J. Lipid Res., 1992, 33, 141–
166.
12 J. P. Segrest, M. K. Jones, H. D. Loof and N. Dashti, J. Lipid
Res., 2001, 42, 1346–1367.
13 M. H. Dominiczak and M. J. Caslake, Ann. Clin. Biochem.,
2011, 48, 498–515.
14 J. P. Kane, Annu. Rev. Physiol., 1983, 45, 637–650.
15 Adult Treatment Panel III (ATP III), Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults, National
Cholesterol Education Program (NCEP), USA, 2002.
16 T. Eleni, K. Bairaktari and I. Seferiadis, J. Cardiovasc.
Pharmacol. Ther., 2005, 10, 45–54.
17 K. A. Rye and P. J. Barter, Biochim. Biophys. Acta, 2012, 1821,
473–480.
18 J. P. Despres, Nat. Rev. Cardiol., 2013, 10, 70–72.
19 G. R. Warnick, M. Nauck and N. Rifai, Clin. Chem., 2001, 47,
1579–1596.
20 G. Hu, Y. Cui, P. Jousilahti, J. Sundvall, C. J. Girman,
R. Antikainen, T. Laatikainen and J. Tuomilehto, Eur. J.
Prev. Cardiol., 2013, 20, 89–97.
21 G. R. Warnick, Clin. Chem., 1995, 41, 1427.
22 M. D. Bethesda, Clin. Chem., 1995, 41, 1414–1420.
23 S. Caudill, G. Cooper, S. Smith and G. Myers, Clin. Chem.,
1998, 44, 1650–1658.
24 G. R. Warnick, M. M. Kimberly, P. P. Waymack, E. T. Leary
and G. L. Myers, Labmedicine, 2009, 39, 481–490.
25 P. S. Bachorik, Clin. Chem., 1995, 41, 1414–1420.
26 M. Nauck, G. R. Warnick and N. Rifai, Clin. Chem., 2002, 45,
236–254.
27 G. R. Cooper, Clin. Chem., 1986, 32, 921.
28 W. T. Friedewald, Clin. Chem., 1972, 18, 499–502.
29 J. Timo´n-Zapata, Clin. Biochem., 2011, 44, 1451–1456.
30 K. Tanno, T. Okamura, M. Ohsawa, T. Onoda, K. Itai,
K. Sakata, M. Nakamura, A. Ogawa, K. Kawamura and
A. Okayama, Clin. Chim. Acta, 2010, 411, 1774–1780.
31 D. A. Tighe, I. S. Ockene, G. Reed and R. Nicolosi, Clin.
Chim. Acta, 2006, 365, 236–242.
32 I. Turkalp, Anadolu Kardiyol Derg., 2005, 5, 13–17.Anal. Methods, 2013, 5, 3612–3625 | 3623
Analytical Methods Critical Review33 E. Bairaktari, M. Elisaf, C. Tzallas, S. A. Karabina,
A. D. Tselepis, K. C. Siamopoulos and O. Tsolas, Clin.
Biochem., 2001, 34, 593–602.
34 M. Rostami, Clin. Biochem., 2011, 44, S147.
35 A. J. Tremblay, H. Morrissette, J. Gagne´, J. Bergeron,
C. Gagne´ and P. Couture, Clin. Biochem., 2004, 37, 785–790.
36 M. M. Kimberly, E. T. Leary, T. G. Cole and P. P. Waymack,
Clin. Chem., 1999, 45, 1803–1812.
37 J. H. Contois, Clin. Chim. Acta, 1999, 282, 1.
38 M. Nauck, Clin. Chem., 1995, 41, 1761–1767.
39 F. Shang, E. Guihen and J. D. Glennon, Electrophoresis,
2012, 33, 105–116.
40 N. Ruecha, W. Siangproh and O. Chailapakul, Talanta,
2011, 15, 1323–1328.
41 S. Usui, Clin. Chem., 2000, 46, 63–72.
42 M. Okazaki, S. Usui, M. Nakamura and S. Yamashita, Clin.
Chim. Acta, 2008, 395, 62–67.
43 H. Osman and K. C. Yap, MJAS, 2006, 10, 205–210.
44 M. Okazaki, Clin. Chem., 1997, 43, 1885–1890.
45 J. Dong, H. Guo and R. Yang, J. Lipid Res., 2011, 52, 383–388.
46 J. Dong, H. Guo, R. Yang, H. Li, S. Wang, J. Zhang, W. Zhou
and W. Chen, Clin. Chim. Acta, 2012, 413, 1071–1076.
47 R. W. Burke, B. I. Diamondstone and R. A. Velapoldi, Clin.
Chem., 1974, 20, 794–801.
48 A. Zlatkis, B. Zak and A. J. Boyle, J. Lab. Clin. Med., 1953, 41,
486–492.
49 W. Richmond, Clin. Chem., 1973, 19, 1350–1356.
50 C. C. Allain, L. S. Poon, C. S. G. Chan, W. Richmond and
P. C. Fu, Clin. Chem., 1974, 20, 470–475.
51 F. O. Sale`, S. Marchesini, P. H. Fishman and B. Berra, Anal.
Biochem., 1984, 142, 347–350.
52 G. R. Warnick, J. Benderson and J. J. Albers, Clin. Chem.,
1982, 28, 1379–1388.
53 Y. C. Kim and T. Nishida, J. Biol. Chem., 1979, 254, 9621–
9626.
54 G. R. Warnick, J. Lipid Res., 1978, 19, 65–76.
55 M. Lopes-Virella, Clin. Chem., 1977, 23, 882.
56 C. J. Briggs, Ann. Clin. Biochem., 1981, 18, 177–181.
57 N. Rifai, G. R. Warnick, J. R. McNamara, J. D. Belcher,
G. F. Grinstead and I. D. Frantz Jr, Clin. Chem., 1992, 38,
150–160.
58 W. G. Miller, G. L. Myers, I. Sakurabayashi,
L. M. Bachmann, S. P. Caudill, A. Dziekonski, E. Selvin,
M. Kimberly, W. J. Korzun, E. T. Leary, K. Nakajima,
M. Nakamura, G. Nilsson, R. D. Shamburek,
G. W. Vetrovec, G. R. Warnick and A. T. Remaley, Clin.
Chem., 2010, 56, 977–986.
59 A. Kondo, Clin. Chem., 1999, 45, 1974.
60 T. Kakuyama, S. Kimura and Y. Hasiguchi, Clin. Chem.,
1994, 40, A1104.
61 M. Nakamura, Y. Kayamori, S. Sato and T. Shimamoto, in
Focus on cholesterol research, ed. M. A. Kramer, Nova
biomedical book, New York, 2006.
62 H. Sugiuchi, Y. Uji, H. Okabe, T. Irie, K. Uekama,
N. Kayahara and K. Miyauchi, Clin. Chem., 1995, 41, 717–
723.
63 M. L. Arranz-Pe~na, Clin. Chem., 1998, 44, 2499.3624 | Anal. Methods, 2013, 5, 3612–362564 K. Nakanishi, M. Nakamura and K. Hino, Methods for
quantitating high-density lipoprotein cholesterol, C12Q1/26,
JP, 1998.
65 K. Hino, M. Nakamura and M. Manabe, Method for
quantitatively determining cholesterol, C12Q1/44, JP, 1998.
66 M. Naucka, W. Ma¨rz and H. Wieland, Clin. Chem., 1998, 44,
1443–1451.
67 N. Harris, V. Galpchian, J. Thomas, E. Iannotti, T. Law and
N. Rifai, Clin. Chem., 1997, 43, 816–823.
68 M. J. Lin, Clin. Chem., 1998, 44, 1050.
69 Y. Kurosaki, K. Hachimura and Z. Ogawa, Clin. Chim. Acta,
2009, 401, 110–113.
70 M. Nakamura, Y. Taniguchi, M. Yamamoto andM. Manabe,
Method of pretreatment of sample for quantitating cholesterol
and method for quantitating cholesterol in specic
lipoproteins, C12Q1/26, USA, 2009.
71 H. Tamura, S. Nishino, T. Yamaguchi and K. Hino, Test
piece for measuring HDL-cholesterol, C12Q1/44, JP, 2009.
72 S. Yamamoto, M. Yamamoto and K. Nakanishi, Method of
measuring lipid in specic lipoprotein, C12Q1/61, JP, 2011.
73 C. Mayeld, Clin. Chem., 1979, 25, 1309–1313.
74 J. Lawlor, Clin. Chem., 1998, 44, A79–A79.
75 W. G. Miller, Clin. Chem., 2002, 48, 489.
76 H. Sugiuchi, Clin. Chem., 1998, 44, 522–531.
77 G. Pembouong, N. Morellet, T. Kral, M. Hof, D. Scherman,
M. Bureau and N. Mignet, J. Controlled Release, 2011, 151,
57–64.
78 M. Esteban-Salan, Clin. Chem., 2000, 46, 1121–1131.
79 M. Okada, J. Lab. Clin. Med., 1998, 132, 195–201.
80 T. Kakuyama, Clin. Chem., 2001, 47, A55–A56.
81 J. H. Contois, G. R. Warnick and A. D. Sniderman, J. Clin.
Lipidol., 2011, 5, 264–272.
82 P. Bayer, F. Veinberg, R. Couderc, C. Cherls, M. Cambillau,
C. Cosson, S. Fradin, P. Gillery, J. Steinmetz, A. Legrand,
M. Egloff and I. Beucler, Ann. Biol. Clin., 2005, 63, 27–41.
83 Y. Iizuka, M. Ishijima, T. Kato, T. Nanmoku, K. Kuwa,
Y. Kawakami and K. Isobe, J. Anal. Bio-Sci., 2012, 35, 168–
178.
84 K. L. Chien, H. C. Hsu, T. C. Su, M. F. Chen, Y. T. Lee and
F. B. Hu, J. Lipid Res., 2007, 48(11), 2499–2505.
85 M. Nakamura, I. Koyama, H. Iso, S. Sato, M. Okazaki,
M. Kiyama, T. Shimamoto and M. Konishi, J. Atheroscler.
Thromb., 2009, 16, 756–763.
86 H. W. Vesper, P. W. F. Wilson and N. Rifai, Clin. Chem.,
2012, 58, 523–527.
87 S. M. Boekholdt, B. J. Arsenault, S. Mora, T. R. Pedersen,
J. C. LaRosa, P. J. Nestel, R. J. Simes, P. Durrington,
G. A. Hitman, K. M. Welch, D. A. DeMicco,
A. H. Zwinderman, M. B. Cleareld, J. R. Downs,
A. M. Tonkin, H. M. Colhoun, J. r. Gotto, P. M. Ridker
and J. J. Kastelein, JAMA, J. Am. Med. Assoc., 2012, 307,
1302–1309.
88 S. S. Martin, M. J. Blaha, M. B. Elshazly, E. A. Brinton,
P. P. Toth, J. W. McEvoy, P. H. Joshi, K. R. Kulkarni,
P. D. Mize, P. O. Kwiterovich, A. P. DeFilippis,
R. S. Blumenthal and S. R. Jones, J. Am. Coll. Cardiol.,
2013, DOI: 10.1016/j.jacc.2013.01.079.This journal is ª The Royal Society of Chemistry 2013
Critical Review Analytical Methods89 H. E. Deventer, W. G. Miller, G. L. Myers, I. Sakurabayashi,
L. M. Bachmann, S. P. Caudill, A. Dziekonski, S. Edwards,
M. M. Kimberly, K. Nakajima, M. Nakamura, G. Nilsson,
R. D. Shamburek and G. W. Vetrovec, Clin. Chem., 2011,
57, 490–501.
90 V. Gubala, L. F. Harris, A. J. Ricco, M. X. Tan and
D. E. Williams, Anal. Chem., 2012, 84, 487–515.
91 J. R. Taylor, Ann. Pharmacother., 2004, 38, 1252–1257.
92 A. Warsinke, Anal. Bioanal. Chem., 2009, 393, 1393–1405.
93 A. Plu¨ddemann, M. Thompson, C. P. Price, J. Wolstenholme
and C. Heneghan, Br. J. Gen. Pract., 2012, 62, e224–e226.
94 V. R. Panz, F. J. Raal, J. Paiker, R. Immelman and H. Miles,
Cardiovasc. J. South Af., 2005, 16, 112–117.
95 J. Me´ndez-Gonza´lez, R. Bonet-Marque´s and J. Ordo´~nez-
Llanos, Point of Care: The Journal of Near-Patient Testing &
Technology, 2010, 9, 102–107.
96 The Medical Services Advisory Committee (MSAC), Near
Patient Testing using Cholestech LDX, 2001.
97 M. Carey, C. Markham, P. Gaffney, G. Boran and V. Maher,
Ir. J. Med. Sci., 2006, 175, 30–35.
98 R. A. Dale, L. H. Jensen and M. J. Krantz, Ann.
Pharmacother., 2008, 42, 633–639.
99 J. V. Patel, G. H. Thorpe, L. Springer and E. A. Hughes,
Atherosclerosis, 2011, 218, e8–e9.
100 C. Fang, Sens. Actuators, B, 2011, 155, 545–550.This journal is ª The Royal Society of Chemistry 2013101 I. Karube, K. Hara, H. Mastsuoka and S. Suzuki, Anal. Chim.
Acta, 1982, 139, 127–132.
102 C. S. Pundir, J. Sci. Ind. Res., 2008, 67, 299–306.
103 B. C. O¨zer, H. O¨zyo¨ru¨k, S. S. Çelebi and A. Yıldız, Enzyme
Microb. Technol., 2007, 40, 262–265.
104 Y. J. Shin and J. Kameoka, J. Ind. Eng. Chem., 2012, 18, 193–
197.
105 A. Kumar, R. R. Pandey and B. Brantley, Talanta, 2006, 69,
700–705.
106 H. S. Huang, S. S. Juan and G. G. Guilabult, Clin. Chem.,
1977, 23, 671–676.
107 C. A. S. Andrade, M. D. L. Oliveira and T. E. S. Faulin, in
Biosensors for Health, Environment and Biosecurity, ed.
P. A. Serra, InTech, 2011.
108 S. Chunta, C. Promptmas and C. Cherdchu, International
Journal of Applied Biomedical Engineering, 2009, 2,
24–32.
109 S. Snellings, J. Fuller, M. Pitner and P. W. David, Biosens.
Bioelectron., 2003, 19, 353–363.
110 L. D'Ulivo, J. Saint-Guirons, B. Ingemarsson and
M. Riekkola, Anal. Bioanal. Chem., 2010, 396, 1373–1380.
111 W. Yan, X. Chen, X. Li, X. Feng and J. Zhu, J. Phys. Chem. B,
2008, 112, 1275–1281.
112 H. Kinoshita, M. Torimura, K. Kano and T. Ikeda, Ann. Clin.
Biochem., 1998, 35, 739–744.Anal. Methods, 2013, 5, 3612–3625 | 3625
